Kiniksa Pharmaceuticals (KNSA) - יתרות מזומנים בחישוב למניה

The Kiniksa Pharmaceuticals (KNSA) business model is based on outsourcing production through third-party contractors supported by a robust internal R&D base. The free cash flow per share trend visualizes the current liquidity reserve, where 7.27 serves as the current metric level. ARCALYST sales growth and new molecules drive development, while competent management ensures investor confidence in the company's commercial success.
פילוחים אנליטיים של חברת Kiniksa (KNSA)

This indicator measures the issuer's net liquidity, stripped of volatile factors, allowing for an assessment of the business's intrinsic resilience and the risk of inefficient capital management. For Kiniksa Pharmaceuticals (KNSA), the cash per share confirms a financial reserve to support the uninterrupted operation of research centers and production lines, guaranteeing investors the stable execution of the clinical trial schedule.